Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria
- PMID: 30306296
- DOI: 10.1007/s00394-018-1844-5
Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria
Abstract
Non-alcoholic fatty-liver disease (NAFLD) is now considered one of the leading causes of liver disease worldwide and is associated with metabolic syndrome and obesity. There are several factors contributing to the disease state. Recent research suggests that the intestinal microbiota (IM) and bacterial products may play a role through several mechanisms which include increased energy uptake, intestinal permeability and chronic inflammation. In addition to diet and exercise, treatment options targeting the IM are being investigated and include the use of pre-, pro- and synbiotics as well as the possibility of fecal microbial transfers. This literature review explores the relationship between NAFLD and the IM as well as highlight new IM treatment options that may become available in the near future.
Keywords: Fecal transplant; Gut bacteria; Non-alcoholic fatty liver disease; Obesity; Prebiotics.
Similar articles
-
Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease.Dis Model Mech. 2019 Apr 30;12(5):dmm039206. doi: 10.1242/dmm.039206. Dis Model Mech. 2019. PMID: 30971408 Free PMC article.
-
Microbiota, Obesity and NAFLD.Adv Exp Med Biol. 2018;1061:111-125. doi: 10.1007/978-981-10-8684-7_9. Adv Exp Med Biol. 2018. PMID: 29956210 Review.
-
Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.Front Med. 2018 Dec;12(6):645-657. doi: 10.1007/s11684-018-0645-9. Epub 2018 Sep 4. Front Med. 2018. PMID: 30178233 Review.
-
An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesity.Rev Esp Enferm Dig. 2019 Apr;111(4):275-282. doi: 10.17235/reed.2019.6068/2018. Rev Esp Enferm Dig. 2019. PMID: 30810328
-
Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.J Microbiol. 2018 Dec;56(12):855-867. doi: 10.1007/s12275-018-8346-2. Epub 2018 Oct 25. J Microbiol. 2018. PMID: 30377993 Review.
Cited by
-
Association between Inflammatory Biomarkers and Nutritional Status in Fatty Liver.Clin Nutr Res. 2020 Jul 28;9(3):182-194. doi: 10.7762/cnr.2020.9.3.182. eCollection 2020 Jul. Clin Nutr Res. 2020. PMID: 32789148 Free PMC article.
-
Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice.Gut Microbes. 2021 Jan-Dec;13(1):1-20. doi: 10.1080/19490976.2021.1930874. Gut Microbes. 2021. PMID: 34125646 Free PMC article.
-
Effect of Wakame and Carob Pod Snacks on Non-Alcoholic Fatty Liver Disease.Nutrients. 2019 Jan 4;11(1):86. doi: 10.3390/nu11010086. Nutrients. 2019. PMID: 30621142 Free PMC article.
-
Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal-Regulating Kinase 1 Pathways.Hepatology. 2019 Oct;70(4):1099-1118. doi: 10.1002/hep.30597. Epub 2019 Apr 22. Hepatology. 2019. PMID: 30820969 Free PMC article.
-
Impact of urbanization on gut microbiome mosaics across geographic and dietary contexts.mSystems. 2024 Oct 22;9(10):e0058524. doi: 10.1128/msystems.00585-24. Epub 2024 Sep 17. mSystems. 2024. PMID: 39287374 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical